Fezolamine

Fezolamine

Fezolamine is a pharmacological compound that belongs to the class of antidepressant drugs. It was developed in the late 20th century and has been studied for its potential therapeutic effects in treating depression and anxiety disorders.

History

Fezolamine was first synthesized in the 1970s by the pharmaceutical company Upjohn. It was part of a series of compounds developed with the aim of finding a new, effective antidepressant. However, despite promising initial results, Fezolamine was never marketed.

Pharmacology

Fezolamine is a serotonin-norepinephrine reuptake inhibitor (SNRI), which means it works by increasing the levels of serotonin and norepinephrine in the brain. These neurotransmitters are known to play a key role in mood regulation, and their imbalance is thought to contribute to depression and anxiety disorders.

Clinical Trials

In clinical trials, Fezolamine showed potential as an antidepressant and anxiolytic. However, it also demonstrated a high incidence of side effects, including nausea, dizziness, and insomnia. These side effects, combined with the availability of other, more effective antidepressants, led to the discontinuation of Fezolamine's development.

Current Status

Today, Fezolamine is primarily of interest to researchers studying the history and development of antidepressant drugs. It is not currently available for prescription or over-the-counter use.

See Also

• Antidepressant
• Serotonin-norepinephrine reuptake inhibitor
• Upjohn

‎

‎